Agios Pharmaceuticals, Inc.
Common Stock · USD · NASDAQ
Price
$29.5
Cap
—
Earnings
—
30d Trend
+19.6%
63% annualised over 90 days
BRAIN47 SIGNAL
Raw weighted: 37×Macro 0.99 (−1%)=37
RISK
QUALITY
MOMENTUM
TECHNICAL
FUNDAMENTALS
Macro: neutral (×0.99) - Fear/Greed: 64 (Greed) - Data: 100%
BRAIN47 HORIZON ANALYSIS
Short-term opportunity — technical setup
BRAIN47'S ASSESSMENT
I rate Agios Pharmaceuticals, Inc. at 37/100 — a WEAK reading on the Brain47 Signal. The strongest factor is technical at 53/100. I classify this as a speculative position with the strongest thesis on a short-term horizon.
PAST PERFORMANCE
1 MONTH
+8.4%
3 MONTHS
+0.6%
12 MONTHS
-4.5%
Trailing returns — past performance, not a projection.
DETAILED ANALYSIS
Short-term opportunity — technical setup. Technical (53) and Momentum (37) are the primary strengths. I note that fundamentals is the weakest area at 15/100 — this warrants monitoring. Historical volatility is elevated at 63%. I classify this as a speculative position — elevated volatility at 63% and smaller market cap define the opportunity.
Want full analysis on every stock?
Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.
Join Brain47 — FreeGenerated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.